Holen Sie sich die Stockscreener-App
1.96
0.51%
0.00
Schlusskurs vom Vortag:
$1.96
Offen:
$1.99
24-Stunden-Volumen:
617.60K
Relative Volume:
2.16
Marktkapitalisierung:
$116.82M
Einnahmen:
$8.38M
Nettoeinkommen (Verlust:
$-27.19M
KGV:
-1.7982
EPS:
-1.09
Netto-Cashflow:
$-13.59M
1W Leistung:
-2.48%
1M Leistung:
+42.75%
6M Leistung:
+178.05%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.93
$2.06
1-Wochen-Bereich:
$1.85
$2.1596
52-Wochen-Spanne:
$0.65
$2.1596
Opus Genetics Inc Stock (IRD) Company Profile
Firmenname
Opus Genetics Inc
Sektor
Branche
Telefon
248-681-9815
Adresse
8 DAVIS DRIVE, DURHAM
Vergleichen Sie IRD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
1.95 | 117.42M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.31 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.47 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.26 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.58 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-11 | Eingeleitet | Craig Hallum | Buy |
| 2024-11-13 | Fortgesetzt | H.C. Wainwright | Buy |
Opus Genetics Inc Aktie (IRD) Neueste Nachrichten
Is Opus Genetics Inc. (R3X1) stock at risk of policy regulationInsider Selling & Stepwise Trade Execution Plans - newser.com
Opus Genetics Inc. stock momentum explained2025 Winners & Losers & Safe Entry Momentum Tips - newser.com
Real time breakdown of Opus Genetics Inc. stock performanceJuly 2025 Highlights & Reliable Breakout Forecasts - newser.com
Applying chart zones and confluence areas to Opus Genetics Inc.2025 Retail Activity & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Opus Genetics Inc. stock a safe haven assetWeekly Stock Recap & Consistent Growth Equity Picks - newser.com
Price action breakdown for Opus Genetics Inc.July 2025 Gainers & Weekly High Return Forecasts - newser.com
Can Opus Genetics Inc. stock maintain operating marginsJuly 2025 Sentiment & Stepwise Trade Execution Plans - newser.com
Does Opus Genetics Inc. stock trade at a discount to peers2025 Historical Comparison & Real-Time Stock Entry Alerts - newser.com
Can Opus Genetics Inc. stock hit analyst price targetsQuarterly Earnings Summary & Fast Exit and Entry Strategy Plans - newser.com
Opus Genetics (NASDAQ:IRD) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
How big funds are accumulating Opus Genetics Inc. (R3X1) stockJuly 2025 Sentiment & Low Drawdown Momentum Trade Ideas - newser.com
Can trapped investors hope for a rebound in Opus Genetics Inc.Earnings Performance Report & Risk Managed Investment Entry Signals - newser.com
What analysts say about Opus Genetics Inc R3X1 stockCapital Gains Strategies & Exceptional Profit Portfolio - earlytimes.in
Combining machine learning predictions for Opus Genetics Inc.Analyst Upgrade & Risk Adjusted Buy/Sell Alerts - newser.com
What data driven models say about Opus Genetics Inc.’s futureEarnings Overview Report & Stepwise Entry/Exit Trade Alerts - newser.com
Opus Genetics reports positive pediatric data from LCA5 gene therapy study - Eyes On Eyecare
Opus Genetics, Inc. (NASDAQ:IRD) Sees Large Increase in Short Interest - MarketBeat
How Opus Genetics Inc. (R3X1) stock performs in volatility spikesJuly 2025 Final Week & Weekly Setup with High ROI Potential - newser.com
Using R and stats models for Opus Genetics Inc. forecastingQuarterly Trade Review & High Accuracy Trade Alerts - newser.com
Opus Genetics Inc. stock daily chart insightsQuarterly Profit Review & Reliable Breakout Forecasts - newser.com
Opus Genetics (NASDAQ:IRD) Trading Up 4.4%Should You Buy? - MarketBeat
Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025 - GlobeNewswire
Are You Looking for a Top Momentum Pick? Why Opus Genetics, Inc. (IRD) is a Great Choice - sharewise.com
Craig-Hallum Maintains Opus Genetics(IRD.US) With Buy Rating - 富途牛牛
What drives Opus Genetics Inc stock pricePrice Gap Trading Strategies & Capitalize On Fast Trends - earlytimes.in
H.C. Wainwright reiterates Buy rating on Opus Genetics stock, citing positive data - Investing.com Canada
Why pension funds invest in Opus Genetics Inc. (R3X1) stockWeekly Profit Analysis & Real-Time Sentiment Analysis - newser.com
H.C. Wainwright Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛
JonesTrading Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $6 - 富途牛牛
Opus Genetics Reports Positive Pediatric Data from - GlobeNewswire
Magnum Opus: Street drinks in LCA5 gene therapy phase I/II data - BioWorld MedTech
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) - GlobeNewswire
Opus Genetics Shares Encouraging Data From Inherited Retinal Degeneration Study - Nasdaq
Opus Genetics reports positive data from LCA5 gene therapy trial By Investing.com - Investing.com Australia
Opus Genetics reports positive data from LCA5 gene therapy trial - Investing.com India
Opus Genetics reports positive pediatric data from OPGx-LCA5 phase 1/2 trial in Leber congenital amaurosis type 5 (LCA5) - MarketScreener
Finanzdaten der Opus Genetics Inc-Aktie (IRD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Opus Genetics Inc-Aktie (IRD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| YERXA BENJAMIN R | President |
Nov 21 '24 |
Buy |
0.98 |
10,000 |
9,834 |
342,800 |
| Magrath George | Chief Executive Officer |
Nov 15 '24 |
Buy |
1.01 |
90,294 |
91,215 |
483,244 |
| Magrath George | Chief Executive Officer |
Nov 18 '24 |
Buy |
1.02 |
9,706 |
9,943 |
492,950 |
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):